U.S. Markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,447.00-34.00 (-0.76%)
At close: 4:36PM BST
Full screen
Previous Close4,481.00
Open4,477.00
Bid4,352.00 x 6100
Ask4,548.00 x 13000
Day's Range4,418.50 - 4,480.50
52 Week Range3,996.00 - 5,520.00
Volume1,614,494
Avg. Volume2,153,578
Market Cap56.29B
Beta0.62
PE Ratio (TTM)16.66
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.79 (4.93%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • Barrons.com17 hours ago

    Tesaro: Losing Its Edge?

    The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.

  • Barrons.com19 hours ago

    Ovarian Cancer Market Still Up For Grabs

    The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment.

  • AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion
    Zacksyesterday

    AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion

    AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.